

## Systematic Review

# Unravelling the Role of IL-6, TNF-alpha and CRP in Pathogenesis of Coronary Artery Disease: A Systematic Review

Priya Anjali<sup>1\*</sup>, Pothu Ushakiran<sup>2</sup>, Jigar Haria<sup>3</sup>

<sup>1</sup>Department of Biochemistry, Teerthanker Mahaveer Medical College and Research Centre, Teerthanker Mahaveer University, Moradabad, UP, India.

<sup>2</sup>Department of Biochemistry, Teerthanker Mahaveer Medical College and Research Centre, Teerthanker Mahaveer University Moradabad, UP, India.

<sup>3</sup>Department of Medicine, Teerthanker Mahaveer Medical College and Research Centre, Teerthanker Mahaveer University Moradabad, UP, India.



Scan and read the  
article online

**Citation** Anjali P, Ushakiran P, Haria J. Unravelling the Role of IL-6, TNF-alpha and CRP in Pathogenesis of Coronary Artery Disease: A Systematic Review. Iran J Blood Cancer. 2025 Dec 30;17(4): 82-103.



### Article info:

Received: 12 Oct 2025

Accepted: 11 Dec 2025

Published: 30 Dec 2025

### Keywords:

Coronary artery disease

IL-6

TNF-alpha

CRP

Inflammation

### Abstract

**Background:** India has high incidence of cardiovascular disease and coronary artery disease (CAD). Coronary artery disease is attaining epidemic proportions in India. Higher levels of C-reactive protein were connected to an augmented risk of coronary heart disease (CHD). TNF-alpha & IL-6 contribute in the pathogenesis of CHD and their levels are closely linked with the extent of coronary heart disease.

**Aim and objectives:** This objective of this review is to analyze the status of inflammatory markers and to establish their relation with the extent of CAD.

**Methodology:** The literature search for this review was done through databases incorporated are PubMed, Web of sciences, Scopus, Medline, Research Gate and Google scholar. The keywords used were “coronary artery disease”, “inflammatory markers,” and “cytokines in inflammation”. The Preferred Reporting Items for Systematic Research and Meta-Analysis (PRISMA) were used to build this review article.

**Results:** There were 1860 articles found which were relevant to the aim of our review, out of which only 57 fulfilled the inclusion criteria. A substantial variability across the studies was found. To figure out its correlation with inflammatory processes, these studies employed a variety of inflammatory markers. Most studies found a high level of inflammatory markers such as IL-6, TNF-alpha, and CRP in patients with coronary artery disease and cardiovascular disease.

**Conclusion:** Data from the literature searched highlighted a significant association between inflammatory markers and CAD.

### \* Corresponding Author:

Priya Anjali

**Affiliation:** Department of Biochemistry, Teerthanker Mahaveer Medical College and Research Centre, Teerthanker Mahaveer University, Moradabad, UP, India.

**E-mail:** [priyaanjali01116@gmail.com](mailto:priyaanjali01116@gmail.com)

## 1. INTRODUCTION

Coronary artery disease is a common cardiac disorder in which atherosclerotic plaque builds up in the lumen of an artery supplying the heart. This results in reduced blood flow and oxygen supply to the myocardium. (1) In 2022, there were 315 million prevalent cases of coronary artery disease seen globally. (2) Global burden of disease estimates state that the prevalence of coronary artery disease worldwide was 154 million in 2016 which is 32.7 % of total cardiovascular disease and 2.2% of the total global burden of disease. (3) Mangala Rao et al. in conducting a systematic review of coronary artery disease in 2015 of 3885 studies and 288 observational studies done in India of coronary artery disease, found that the prevalence was 2.5%-12.6% in urban areas and 1.4%-4.6% in rural areas. Moreover, it was also found that the prevalence of different risk factors was smoking 8.9-40.5%, hypertension 13.1-36.9%, and diabetes mellitus 0.2-24.0%. (4) In the 60th round of surveys conducted by the National Statistical Survey Organization (NSSO) in 2004-2005, it was reported that the prevalence rate of CHD was 10% in the urban population and 4% in the rural population. (5) Prevalence rates evaluated by different studies according to year and place of studies have been shown in the **Table 1** below.

CAD is the inflammatory disease which indicates the formation atherosclerotic plaque within the coronary arteries of the heart. The atherosclerotic plaque leads to blockage of coronary artery resulting in inadequate supply of oxygen to cardiac muscles. (11) There are many risk factors related with CAD and plaque buildup, some can be controlled and some cannot be controlled. The risk factors that can be manageable are high blood pressure, raised cholesterol levels, diabetes mellitus, obesity, lack of exercise, nutritionally deficient diet, and smoking. The risk factors that cannot be managed are age, gender family history, and race. (12)

Inflammation participated in the progression and development of atherosclerotic plaque. (13) In this review, we will discuss the role of different inflammatory markers associated with the pathophysiology of atherosclerosis thereby resulting in coronary artery disease. Some of the inflammatory markers are: IL-6, IL-1, IL-18, TNF-alpha, C-reactive protein (CRP), lipoprotein phospholipase A2, and metalloproteinase (14), White blood cells (WBC)/Leukocytes, Macrophage colony-stimulation factor (MCSF), Monocyte chemoattractant protein-1 (MCP1/CCL2). (15) C-reactive protein (CRP) is acute-phase protein that can be elevated by as much as 1,000-fold in the zone of inflammation. (16) C-reactive protein is the final product of

inflammation-related events. CRP has a direct proinflammatory effect on the endothelial tissue due to stimulation of proinflammatory activity inducible nitric oxide synthase (NOS) and inhibition of atheroprotective endothelial NOS. This shows that CRP may reflect the overall impact of local vascular inflammation. (17) CRP causes vascular smooth muscle cells to undergo apoptosis which contributes to plaque instability and has a procoagulant effect through suppression of prostacyclin. CRP can be useful in predicting long-term survival in acute coronary syndrome independent of LDL levels and it shows additional prognostic value of myocardial necrosis markers. (18) Paul M Ridker et al. had shown in their study that groups having high levels of CRP in patients with metabolic syndrome are at more risk of cardiovascular disease. (19) TNF-alpha is the cytokine involved in inflammation that participated in the pathophysiology and progression of cardiovascular disorder. Also, the overexpression of TNF-alpha leads to the pathogenesis of various disorders like arthritis, coronary artery disease, and myocardial infarction. Polymorphism associated with the TNF-alpha gene may affect cardiovascular problems. (20) IL-6 is a pleiotropic cytokine that is involved in humoral and cellular immune responses related to inflammation, host defense, and tissue damage. (21) Interleukin-6 is mostly expressed by leukocytes, especially by active macrophages, and also expressed by smooth muscle and endothelial cells. The primary cause of CAD is the pathophysiology of atherosclerosis which is significantly influenced by IL-6 signalling. (22)

## 2. METHODS

The review was conducted in accordance with the guidelines outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Statement.

### 2.1. Eligibility criteria

This review included original research articles, meta-analyses and systematic reviews analysing the association of inflammatory markers such as IL-6, TNF-alpha and CRP with coronary artery disease and its severity. Studies relevant to the inflammatory markers in CAD patients and studies associating these inflammatory markers with the severity of the disease were included. Studies only in English language were considered for the inclusion in this review. Studies published between 1990 to 2023 were included. Exclusion criteria comprise of studies which particularly not related to status of inflammatory markers specially IL-6, TNF-alpha and CRP in CAD patients or there was no correlation of

**Table 1.** Prevalence of CAD in India.

Authors	Year	Place	Sample size	CAD%
Anand Krishnan et al.[6]	2012	Delhi NCR (2nd survey)	2052	14.1
	1994	Delhi NCR (1 <sup>st</sup> survey)	3048	10.3
Murthy PD et al.[7]	2012	Andhra Pradesh	534	5.4
Rajeev B et al.[8]	2009	Himachal Pradesh	812	4.1
Kamili M et al.[9]	2007	Jammu & Kashmir	3128	7.5
Clara Chow et al.[10]	2004	Andhra Pradesh	345	2.5

these markers with severity. Exclusion criteria covered non-scientific articles, articles published before 1990 and after 2023 and also the articles which were published in language other than English. Moreover, in addition to relevance-based exclusions, duplicates, incomplete data, commentary articles, conference abstracts that do not include full manuscripts, and non-peer-reviewed sources were excluded to preserve the quality and consistency of the data. A number of potentially relevant articles were excluded owing to language barriers or the absence of full-text access. Studies not in English were excluded mainly because of translation limitations and the lack of trustworthy linguistic resources, which could have compromised the accuracy of data extraction and interpretation. We acknowledge that this introduces a potential language bias, which may result in the omission of significant insights published in other languages.

The research question was developed using the PICO framework. The “Population(P)” consisted coronary artery disease (CAD) or undergoing coronary angiography, both stable and unstable presentations, “Intervention (I)” defined as elevated serum levels of inflammatory biomarkers: Interleukin-6 (IL-6), Tumor Necrosis Factor-alpha (TNF- $\alpha$ ), and C-reactive protein (CRP), healthy individuals or patients without CAD, or those with lower levels of IL-6, TNF- $\alpha$ , and CRP are defined as “Comparison (C)”. “Outcome (O)” was association between inflammatory marker and presence, severity or extent of CAD (e.g. gensini or SYNTAX score) on coronary angiography also comparison between different types of CAD (NSTEMI VS STEMI, obstructive vs non-obstructive, SAP vs USAP vs ACS). Hence, the formulated question was as follows: Is there an association between elevated levels of inflammatory biomarkers- IL-6, TNF-alpha and CRP and CAD and the severity based on angiography?

## 2.2. Information sources

Therefore, we conducted a comprehensive review of the titles and abstracts within the two chosen databases PubMed, Scopus and Medline which are recognized for indexing a wide range of high-impact, peer-reviewed publications in English. The key words used for literature search in the database are “inflammatory marker”, “coronary artery disease” or IL-6, TNF-alpha, CRP in coronary artery disease and “association of inflammatory markers with severity”. Further articles were discovered by examining cross-references to enhance the search. The systematic review was conducted in accordance with the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. Nonetheless, future reviews could be improved through multilingual collaboration to foster inclusivity and comprehensiveness. Both qualitative and quantitative studies were reviewed. Qualitative research included literature reviews, systematic reviews, meta-analyses and scoping reviews. For quantitative studies case-control, prospective and retrospective cohort, and experimental studies were included.

## 2.3. Search strategy

For the analysis of the inflammatory biomarker profile in patients with CAD, a systematic review search was done in the databases of PubMed, Scopus, and Medline.


The key words used for literature search in the database are “inflammatory marker”, “coronary artery disease” or IL-6, TNF-alpha, and CRP in coronary artery disease. Further articles were discovered by examining cross-references to enhance the search. The systematic review was conducted in accordance with the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines.

## 2.4. Selection Process

Relevant citations and references extracted from all recognised studies were reviewed to make sure of full-scale reporting. The screening and selection were done through Mendeley version 1.19.4 reference management software through which all the citations were imported. Selection process included 3 stages in which first stage was to identify the duplicate study and these duplicates were automatically and manually identified and removed. In 2nd stage titles of and abstracts were screened and in the final 3rd stage all the full text articles included were thoroughly reviewed. In addition, relevant citations and references from all identified studies were assessed to ensure complete coverage. The screening and selection process was performed utilizing Mendeley version 1.19.4 reference management software, following a systematic three-phase approach. During Phase I, duplicate records were discarded. Phase II included the screening of article titles and abstracts, whereas Phase III comprised a thorough review of the full-text articles selected from the earlier phase.

**Figure 1** shows a schematic representation of the steps associated with the literature search of our systematic review. During the preliminary search, a total of 1860 articles were identified (PubMed-848, Scopus-803, Medline-208). After elimination of 1225 replicate studies, 635 studies were selected for further review. Then we excluded 526 non-relevant studies (such as CAD associated with some other disease and studies that did not fulfil the selection criteria and exclusion criteria), studies published in non-English languages, lack of full-text access, and availability of only abstract. Then 109 studies were screened for the eligibility to be enrolled in this review and 24 research studies were excluded because of not relevant to aim and objective of our systematic review. A total of 85 full-text articles were evaluated for eligibility based on the established inclusion and exclusion criteria. 19 full text articles which do not meet the inclusion and exclusion criteria were excluded. Also 9 studies containing narrative review were excluded. Remaining 57 studies are included in this systematic review. Two independent reviewers (PUK and PA) evaluated the titles and abstracts of all identified studies. To guarantee reliability and reduce bias, they adhered to a standardized protocol for selection and data extraction. Any discrepancies that arose during the selection or extraction phases were addressed through discussions among the reviewers. If disagreements persisted, a third reviewer (JH) was brought in to help reach a consensus. In instances where immediate consensus was not achievable, the study was collectively re-evaluated prior to making a final decision. This approach

ensured consistency, minimized bias, and upheld the integrity of the review.



**Figure 1.** Study selection flowchart. From 1,860 records identified, 635 remained after removing duplicates. After screening titles and abstracts, 109 articles were reviewed, with 85 full texts assessed. In total, 57 studies were included.

## 2.5. Data extraction and analysis

For every study included, a systematic data extraction method was utilized to gather essential information which encompassed the author, year of publication, country, type of study, sample size and findings of each study. To guarantee precision and uniformity, the reviewers worked together to scrutinize the extracted data, thereby reducing discrepancies in interpretation.

This review showcases its findings by employing a narrative synthesis strategy, adhering to the PRISMA guidelines to comprehensively recognize all available evidence and accentuate essential characteristics.

## 2.6. Risk of bias assessment

Three independent reviewers (PA, UK, and JH) performed assessments of the risk of bias in the selected articles. The Newcastle–Ottawa Scale (NOS) was employed to thoroughly evaluate the quality of risk of bias for each article (23). In the case of cohort and cross-sectional studies the NOS assessed the selection of study groups (both exposed and non-exposed), their comparability, and the evaluation of

outcomes. Conversely, for case-control studies, the NOS examined the selection of study groups (cases and controls), their comparability, and the determination of exposure for both cases and controls. A total of eight items across the three domains could receive a star rating, with each item being assigned a minimum of one star and a maximum of two stars. Studies that achieved a total score of seven to nine stars were classified as high quality, those scoring four to six stars were deemed fair quality, and those with one to three stars were categorized as low quality. NOS assessment for risk of bias of cohort, cross-sectional and case-control studies are shown in **Table 2**, **Table 3** and **Table 4** respectively. Cochrane scale (24) for randomized controlled trial is shown in **Table 5** and for animal model SYRCLE (25) was used shown in **Table 6**.

### 3. RESULTS

A total of 57 studies were reviewed that satisfied the inclusion criteria., 34 studies showed a relationship between IL-6 and coronary artery disease (CAD) summarized in **Table 7**. Furthermore, **Table 8** shows 12 studies reflecting relationship of TNF- $\alpha$  with CAD and 21 studies of CRP and CAD are shown in **Table 9**. The results indicated that the levels of the inflammatory markers IL-6, TNF- $\alpha$ , and CRP were elevated in patients with coronary artery disease in comparison to the control group, and these markers demonstrated a correlation with the severity of the disease. 15 studies demonstrated a correlation between C-reactive protein, TNF- $\alpha$ , and IL-6 with coronary artery disease (CAD) and its severity, as illustrated in **Table 10**.

### 4. DISCUSSIONS

The current research systematically explores the connection between inflammatory markers and the incidence of coronary artery disease. The inflammatory parameters that were studied include Interleukin-6 (IL-6), Tumor necrosis factor-alpha (TNF-alpha) and C-reactive protein (CRP). Elevated levels of these inflammatory markers are commonly linked to adverse outcomes of coronary artery disease leading to a increased chance of cardiac failure, myocardial infarction leading to death.

#### 4.1. Inflammatory Markers and CAD Association

Inflammatory markers and CAD were strongly correlated in nearly all of the studies reviewed. The majority of the studies showed an association between IL-6 and coronary artery disease and fewer studies showed an association of TNF-alpha with coronary artery disease. Among 57 studies

reviewed for this systematic review, finding from 34 studies have revealed a link between interleukin-6 (IL-6) and the development of coronary artery disease, and 12 studies reflected a relationship between TNF-alpha and CAD. 21 studies mentioned in **Table 9** showed the relationship between serum levels of CRP and CAD. But very few studies compared all three inflammatory parameters IL-6, TNF-alpha, and CRP together. Studies such as those done by Bouzidi N et al. (26), Fadhil Jaafar A. et al. (27), Shen L et al.(34), Zhou M et al.(35), Schlitt A. et al. (45), Luc G. et al. (48) showed that concentration of IL-6 in serum were elevated in the group having patients of coronary artery disease than the healthy control group. Studies such as those done by Fadhil Jaafar A. et al. (27), Shen L. et al. (34), and Schlitt A. et al. (42) observed that serum TNF-alpha was elevated in patients of CAD than healthy control (patients without CAD). CRP contributes in the formation of atherosclerotic plaque. Some of the prior studies done by Mahajan N et al. (68), Sharma S B et al. (69), and Zhu M. et al. (66) demonstrated that hs-CRP were elevated in group of subjects with coronary artery disease than controls (group free of CAD) and Luc G. et al. (48) stated The CAD group exhibited higher CRP levels in comparison to the non-CAD group. Sharma S B et al. (69) also showed that hs-CRP was 4.5 times raised than control.

#### 4.2. Inflammatory Markers and Obstructive vs. Non-Obstructive CAD

Of the 57 studies analyzed, only one focused on comparing the serum levels of IL-6 and TNF-alpha in cases of obstructive coronary artery disease versus non-obstructive CAD. Mohammad-Rezaei M et al. (32) concluded in their study that serum concentration of interleukin-6 and TNF- $\alpha$  were more elevated in obstructive than non-obstructive CAD. It was also found that circulating levels of IL-6 in coronary heart disease patients with obstruction in their coronary arteries were 3.32 times that of the subjects with coronary artery patients without obstruction and TNF-alpha levels were 2.25 times in CAD with obstruction that of CAD without obstruction. A characteristic feature of occlusive CAD is the substantial accumulation of atherosclerotic plaque that constricts the coronary arteries and stimulates a heightened inflammatory reaction. IL-6 is generated by stimulated macrophages along with endothelial and SMCs (smooth muscle cells) found in atherosclerotic plaques. Therefore, the larger the burden of plaque, the more IL-6 is produced. (83) Moreover, in obstructive coronary artery disease (CAD), plaques are more likely to become unstable and break apart, initiating acute inflammatory responses. During this process, levels of interleukin-6 (IL-6) increase

**Table 2.** The Newcastle–Ottawa Scale (NOS) for assessment of cohort studies.

Author	Year	Type of study	Representatives of the Exposed Cohort	Selection of the Non-Exposed Cohort	Ascertainment of Exposure	Demonstration that Outcome of Interest Was Not Present at Start of Study	Comparability of Cohorts on the Basis of the Design or Analysis	Assessment of Outcome	Was Follow-Up Long Enough for Outcomes to Occur	Adequacy of Follow-Up of Cohorts	Total score
Gager G. M. et al.[31]	2020	Cohort	*	*	*	*	**	*	*	*	9
Fanola C et al.[34]	2017	Cohort	*	*	*	*	**	*	*	*	9
Su D et al.[40]	2013	Cohort	*	*	*	*	*	*	*		7
Saremi A et al.[43]	2009	Cohort	*	*	*	*	**	*	*		8
Brueckmann M et al.[46]	2004	Cohort	*	*	*	*	*	*	*	*	8
Cesari M et al.[47]	2003	Cohort	*	*	*	*	**	*	*	*	9
Luc G et al.[48]	2003	Cohort	*	*	*	*	**	*	*	*	9
van der Meer IM et al.[49]	2002	Cohort	*	*	*	*	**	*	*		8
Jenny NS et al.[50]	2002	Cohort	*	*	*	*	**	*	*		8
Koukonen H et al.[52]	2001	Cohort	*		*	*	*	*	*	*	8
Lindmark E et al.[53]	2001	Cohort	*	*	*	*	**	*	*	*	9
Biasucci L. M. et al.[59]	1999	Cohort	*	*	*	*	**	*	*	*	9
Khandelwal V et al. [67]	2022	Cohort	*	*	*	*	**	*	*	*	9
Pan H. C. et al. [71]	2015	Cohort	*	*	*	*	**	*	*	*	9
Mahajan N et al. [72]	2009	Cohort	*	*	*	*	**	*	*		8
Sharma S B et al. [73]	2008	Cohort	*	*	*	*	**	*	*		8
Zacho J et al. [74]	2008	Cohort	*	*	*	*	**	*	*	*	9
Mora S et al. [76]	2006	Cohort	*	*	*	*	**	*	*	*	9
Ishikawa T et al. [78]	2003	Cohort	*	*	*	*	*	*	*	*	8
Heeschen C et al. [81]	2000	Cohort	*	*	*	*	**	*	*	*	9
Haverkate F et al. [83]	1997	Cohort	*	*	*	*	**	*	*	*	8
Liuzzo G et al. [84]	1994	Cohort	*	*	*	*	*		*		6

**Table 3.** The Newcastle–Ottawa Scale (NOS) for assessment of cross-sectional studies

Author	Year	Type of study	Representativeness of the Sample	SELECTION (MAX-*****)		Ascertainment of Exposure (Biomarkers)	COMPARABILITY (MAX-**)	OUTCOMES (MAX-***)		TOTAL SCORE
				Sample Size Justification	Non-Respondents			Assessment of Outcome	Statistical Test Appropriateness	
Ling Y et al.[29]	2021	cross-sectional	*			*	*	*	*	5
Tang J et al.[36]	2015	cross-sectional	*			*	*		*	4
Anderson DR et al.[39]	2013	Cross-sectional observational	*			*	*	*	*	5
Tanindi A et al.[42]	2011	cross-sectional	*			*	*	*	*	5
Gotsman I et al.[44]	2008	Cross-sectional observational	*	*		**	*	*	*	7
Schieffer B et al.[57]	2000	cross-sectional	*	*		**		*	*	6
H.G. Rus et al.[61]	1996	cross-sectional	*	*		**		*	*	6
Jianbo Z et al. [68]	2022	cross-sectional	*	*		**		*	*	6
Li X. Y. et al. [85]	2018	cross-sectional	*			**	**	*	**	8
Min X et al. [86]	2017	cross-sectional	*	*		**	**	*	**	9
Al-Tu'maa FJ et al. [87]	2016	cross-sectional	*	*		**		*	**	7
Zebrack JS et al. [88]	2002	cross-sectional	*	*		**	**	*	**	9

**Table 4. The Newcastle–Ottawa Scale (NOS) for assessment of case-control studies.**

Author	Year	Type of Study	Case Definition Adequate	Representativeness of Cases	Selection of Controls	Definition of Controls	Comparability (Max-2)	Ascertainment of Exposure	Same Method of Ascertainment	Non-Response Rate	Total Score
Bouzidi N et al. [24]	2023	Case-Control	*	*	*	*	*	*	*	*	8
Fadhil Jaafar A et al. [25]	2023	Case-Control	*	*	*	*	**	*	*	*	9
Heinisch RH et al. [27]	2022	Case-Control	*	*	*	*	**	*	*	*	9
Douskami H et al. [28]	2021	Case-Control	*	*	*	*	*	*	*	*	7
Mohammad-Rezaei M et al.[30]	2021	Case-Control	*	*	*	*	*	*	*	*	8
Shen L et al. [32]	2019	Case-Control	*	*	*	*	**	*	*	*	9
Zhou M et al. [33]	2019	Case-Control	*	*	*	*	**	*	*	*	9
Schlitt A et al. [45]	2004	Case-Control	*	*	*	*	*	*	*	*	6
Ridker PM et al. [55]	2000	Case-Control	*	*	*	*	**	*	*	*	9
Ridker PM et al. [56]	2000	Case-Control	*	*	*	*	**	*	*	*	9
Biasiussi L. M. et al. [60]	1996	Case-Control	*	*	*	*	**	*	*	*	8
Ridker PM et al. [65]	1999	Case-Control	*	*	*	*	**	*	*	*	9
Maury CPJ et al. [66]	1989	Case-Control	*	*	*	*	*	*	*	*	6
Tajfard M et al. [69]	2018	Case-Control	*	*	*	*	**	*	*	*	8
Zhu M et al. [70]	2018	Case-Control	*	*	*	*	**	*	*	*	8
Haidari M et al. [79]	2001	Case-Control	*	*	*	*	**	*	*	*	8
Danesh J et al. [80]	2000	Case-Control	*	*	*	*	**	*	*	*	9
Tataru MC et al. [82]	1999	Case-Control	*	*	*	*	**	*	*	*	8

**Table 5. The Cochrane scale for assessment of randomized controlled trial.**

Author	Year	Type of study	Bias arising from the randomization process	Bias due to deviations from intended interventions	Bias due to missing outcome data	Bias in measurement of the outcome	Bias in selection of the reported result
Lindmark E et al.[53]	2001		LOW RISK	LOW RISK	LOW RISK	LOW RISK	MODERATE RISK

**Table 6. The SYRCLE scale for assessment of animal model study.**

	Selection Bias (randomization)	Baseline Characteristics	Performance Bias (blinding)	Detection Bias (blinding of assessors)	Attrition Bias	Reporting Bias
Huber SA et al.[58]	1999 Unclear	Low Risk	High Risk/Unclear	High Risk/Unclear	Low Risk	Moderate Risk

**Table 7.** Showing the studies of IL-6 in coronary artery disease.

Sl.no	Author's name	Year	Place	Type of Study	Sample size	Findings
1.	Bouzidi N et al. (26)	2023	Tunisia	Case-control	310-CAD, 210-Controls	The concentration of IL-6 in coronary artery disease patients was elevated in comparison to the control group.
2.	Fadhil Jaafar A et al. (27)	2023	Tehran, Iran	Case-control	176	The levels of IL-6 were markedly elevated in the CAD group compared to the control group.
3.	Djahanpour N et al. (28)	2023	Canada	Systematic review	17 articles	IL-6 levels were closely linked with peripheral artery disease (PAD). IL-6 has the potential to act as a biomarker for the diagnosis and prognosis of peripheral artery disease (PAD).
4.	Heinisch RH et al. (29)	2022	Brazil	Case-control	20- ACS, 20-SA, 20-control	IL-6 increased in ACS patients as compared with stable angina or control subjects. IL-6 levels were elevated in patients with acute coronary syndrome when compared to those with stable angina or control subjects.
5.	Doustkami H et al. (30)	2021	Iran	Case-control	N=90 AMI-30 SAP-30 Control-30	Interleukin (IL)-6 levels were significantly increased in patients with AMI compared with SAP and control groups ( $P < 0.05$ to $P < 0.001$ ). Interleukin-6 concentrations were markedly elevated in patients diagnosed with acute myocardial infarction (AMI) when compared to those in the stable angina pectoris (SAP) and control groups.
6.	Ling Y et al.(31)	2021	China	Cross-sectional Observational Study.	346 ACS-201 SAP-145	IL-6 levels are closely linked to the extent of coronary artery disease in ACS patients undergoing percutaneous coronary intervention. IL-6 levels were significantly higher in the ACS group than SAP with $p$ value $<0.001$ . The levels of IL-6 are strongly associated with the severity of CAD in patients with ACS who are receiving percutaneous coronary intervention. Furthermore, IL-6 levels were markedly elevated in the ACS compared to those with SAP, with a $p$ -value of less than 0.001.
7.	Mohammad-Rezaei M et al. (32)	2021	Iran	Case-control	42-non obstructive CAD (control) 42- obstructive CAD (cases)	IL-6 levels in Coronary artery obstruction increased to 3.32 times that of the subjects with non-obstructive CAD.
8.	Gager G. M. et al. (33)	2020	Austria	Prospective	N=322	Elevated serum IL-6 concentrations are associated with an increased risk of long-term cardiovascular mortality when assessed at the time point of ACS. Elevated levels of serum IL-6 are linked to a heightened risk of long-term cardiovascular mortality when evaluated at the time of acute coronary syndrome (ACS).
9.	Shen L et al. (34)	2019	China	Case-control	138	IL-6 levels were markedly elevated in the CAD group compared to the control group.

10.	Zhou M et al. (35)	2019	Wuhan, China	Case-control	155-CAD 181-Control	Compared to the control subjects, individuals with CAD exhibited significantly higher circulating levels of IL-6.
11.	Fanola C et al. (36)	2017	USA	Cohort	N=4939	The ACS group exhibited a substantial increase in IL-6 levels relative to the control group
12.	Akita K et al. (37)	2017	Japan	Clinical trial	---	IL-6 plays a significant role in the progression of atherosclerosis. Its signalling pathways have been associated with the initiation and destabilization of plaques, as well as negative outcomes during episodes of acute ischemia.
13.	Tang J et al. (38)	2015	China	Cross-sectional	N=81	There was a notable increase in IL-6 expression in the ACS and SAP groups relative to the control group, with a statistically significant p-value of less than 0.01.
14.	Anderson DR et al. (39)	2013	USA	Case-control	73	IL-6 was elevated in AMI compared to CAD and controls.
15.	Su D et al. (40)	2013	China	cohort	N=718	Among hospitalized individuals suffering from coronary artery disease, there is a notable association between serum IL-6 levels and the rates of all-cause and cardiovascular mortality.
16.	Sarwar N et al. (41)	2012	UK	Metanalysis	82 studies	There is a significant cross-sectional link between circulating IL-6 and the likelihood of coronary heart disease occurrence in those without any previous cardiovascular disease history
17.	Tanindi A et al. (42)	2011	Turkey	Cross-sectional	134	IL-6 levels were found to be higher in patients with CAD compared to control subjects, and individuals experiencing acute coronary syndromes exhibited an even more significant rise in IL-6 levels.
18.	Saremi A et al. (43)	2009	Chicago	Cohort	N=306	individuals with STEMI and NSTEMI exhibited markedly elevated levels of IL-6 in contrast to those in the SAP group. A significant correlation was observed between the inflammatory marker IL-6 and coronary atherosclerosis, particularly in subjects who demonstrated less evidence of systemic atherosclerosis.
19.	Gotsman I et al. (44)	2008	Israel	Cross-sectional	201	Patients suffering from acute coronary syndrome exhibited increased levels of IL-6 in contrast to stable patients.
20.	Schlitt A et al. (45)	2004	Germany	Case-control	247-cad, 61-controls	In comparison to the control group, the CAD group exhibited significantly increased levels of IL-6
21.	Brueckmann M et al. (46)	2004	Germany	Cohort study	26	A significant elevation in IL-6 levels was noted in ACS patients compared to the control group, and these levels showed a decline after three months.
22.	Cesari M et al. (47)	2003	USA	Cohort study	N=2225	In patients with coronary heart disease events, stroke events, and coronary heart failure, IL-6 levels were found to be significantly higher than in those who did not have any cardiac events.
23.	Luc G et al. (48)	2003	France	Cohort study	317	Levels of IL-6 were remarkably higher in cases (CHD) than control. With p-value<0.05

24.	van der Meer IM et al. (49)	2002	Netherland	Cohort study	7983	Interleukin-6 has been linked to the development of atherosclerosis.
25.	Jenny NS et al. (50)	2002	USA	cohort	5201	An association was found between IL-6 and elevated atherosclerosis when contrasting the control group with individuals who were free of subclinical cardiovascular disease.
26.	Koukonen H et al. (51)	2001	Finland	Cohort study	263	Elevated levels of IL-6 were linked to a heightened risk of coronary mortality among patients diagnosed with unstable angina pectoris
27.	Lindmark E et al. (52)	2001	Sweden	Prospective Randomized trial	3269	Circulating IL-6 is a robust independent marker of elevated mortality risk in patients suffering from unstable coronary artery disease (CAD), and it can be utilized to identify those individuals who would derive the greatest benefit from an early invasive treatment approach.
28.	Ridker PM et al. (53)	2000	Boston	Case-control study	122- cases 244-control	IL-6 was substantially increased in female with cardiovascular episodes than in women without cardiovascular events with a p-value of 0.003
29.	Ridker PM et al. (54)	2000	Boston	Case-control	Cases-202 Control-202	In the myocardial infarction group, IL-6 levels were significantly greater than those observed in the control group, yielding a p-value of 0.002.
30.	Schieffer B et al. (55)	2000	Finland	Cross-sectional	N=33	Atherectomy samples exhibited a more significant level of IL-6 in comparison to stable coronary segments.
31.	Huber SA et al. (56)	1999	United Kingdom	Cross-sectional	48	IL-6 enhances fatty lesion development in atherosclerosis-prone mice.
32.	Biasucci L. M. et al. (57)	1999	Italy	Cohort	N=43 uneventful course=17 complicated in-hospital course=26	Elevated levels of IL-6 were linked to poor in-hospital outcomes in patients with acute coronary syndrome (ACS). IL-6 was higher in unstable angina and with worsening disease than in patients with an uneventful course.
33.	Biasucci L. M. et al. (58)	1996	America	Case-control	38	Cytokine IL-6 levels were detectable in group with stable and unstable angina than non-diseased control in which IL-6 was not detectable (p<0.01).
34.	H.G. Rus et al. (59)	1996	USA	Cross-sectional	34	IL-6 levels were remarkably increased in normal intima than fibrous plaque with p<0.05 and IL-6 contributes to the atherosclerotic process.

**Table 8.** Showing the studies of TNF-alpha in coronary artery disease.

Sl.no	Author's name	year	place	Type of study	Sample size	Findings
1.	Fadhil Jaafar A et al. (27)	2023	Tehran, Iran	Case-control	176	TNF-alpha levels were notably increased in the coronary artery disease group than those in control group.
2.	Heinisch RH et al. (29)	2022	Brazil	Case-control	20- ACS 20-SA 20-control	Compared to individuals with stable angina or control subjects, patients suffering from acute coronary syndrome (ACS) exhibited an increase in TNF-alpha levels. .
3.	Mohammad-Rezaei M et al. (32)	2021	Iran	Cross-sectional	84 42-non obstructive CAD (control) 42- obstructive CAD (cases)	In patients with obstructive coronary artery disease (CAD), serum levels of TNF-alpha were elevated to 2.25 times the levels observed in non-obstructive CAD.
4.	Shen L et al. (34)	2019	China	Case-control	N=138	TNF-alpha levels were markedly elevated in the coronary heart disease group than control group.
5.	Schlitt A et al. (45)	2004	Germany	Case-control	247-CAD 61-controls	TNF-alpha levels were elevated in the group with coronary heart disease than control.
6.	Lei L et al. (60)	2009	China	Clinical trial	---	In the early phase of lesion development, TNF-alpha contributes to the progression of atherosclerosis.
7.	Gotsman I et al. (44)	2008	Israel	Cross-sectional	N=201	Compared to stable patients, individuals with acute coronary syndrome exhibited elevated levels of TNF-alpha.
8.	Brueckmann M et al. (46)	2004	Germany	Case-control	N=26	The levels of TNF-alpha were markedly elevated in both central and peripheral blood of patients with ACS on days 0 and 1 (p-value < 0.01) when compared to the control group, returning to baseline levels by day 120.
9.	Cesari M et al. (47)	2003	USA	Cohort study	N=2225	TNF-alpha was significantly elevated in subjects with CHD events, stroke events and heart failure than patients with no cardiac events.
10.	Koukonen H et al. (51)	2001	Finland	Cohort study	N=263	Elevated levels of TNF-alpha were linked to a heightened risk of coronary mortality among patients diagnosed with unstable angina pectoris (UAP).
11.	Ridker PM et al. (61)	1999	Boston, United states	Case-control	Cases-272 Control-272	Systemic TNF-alpha concentration was higher in cases (subjects Who developed recurrent coronary event than control (subjects free of recurrent coronary disease)
12.	Maury CPJ et al. (62)	1989	Finland	Case-control study	N=22	Circulating TNF-alpha levels were elevated in patients with myocardial infarction than healthy control.

Table 9. Showing the studies of CRP in coronary artery disease.

Sl.no	Author's name	year	place	Type of Study	Sample size	Findings
1.	Khandelwal V et al. (63)	2022	India	Cross-sectional	N=284	Patients with STEMI showed considerably higher CRP levels relative to patients with unstable angina and chronic stable angina.
2.	Jianbo Z et al. (64)	2022	China	Cross-sectional	N=65	A notable positive correlation ( $P = 0.03$ ) was observed between the volume of the infarct core and the levels of serum hs-CRP. Elevated serum hs-CRP levels can be indicative of the infarct core volume in individuals experiencing acute ischemic syndrome.
3.	Tajfard M et al. (65)	2018	Iran	Case-control	N=2346 Cases-1187 Control-1159	Serum levels of hs-CRP were raised in advanced ischemic heart disease (stenosis $\geq 50\%$ stenosis of at least one coronary artery) than in healthy control ( $p < 0.001$ )
4.	Zhu M. et al. (66)	2018	China	Case-control	N=579 Cases-492 control-87	In the CAD group, hs-CRP levels were significantly greater than those observed in the non-CAD group. Within the CAD group, there was a notable increase in hs-CRP levels corresponding to the number of affected coronary artery branches, whether it was 1, 2, or 3 or more, with statistical significance indicated by $P < 0.01$ .
5.	Tang J et al. (38)	2015	China	Cross-sectional	N=81	The ACS group had a significantly greater hs-CRP than SAP and the control group ( $p\text{-value} < 0.01$ ).
6.	Pan H. C. et al. (67)	2015	China	Cross-sectional	181 Without MACE-142 With MACE- 39	Patients with major adverse cardiovascular events (MACE) have significantly higher hs-CRP than those without MACE ( $p\text{-value} = 0.025$ )
7.	Sarwar N et al. (41)	2012	UK	Meta-analysis	82 studies	There is an association of circulating levels of C-reactive protein with an occurrence of CHD risk with no known history of cardiovascular disease.
8.	Mahajan N et al. (68)	2009	India	Case-control	N=140 Cases-100 Control-40	The CAD group exhibited significantly elevated levels of hs-CRP in comparison to the healthy control group.
9.	Sharma S B et al. (69)	2008	India	Case-control	N=30	A significant increase in hs-CRP levels ( $p < 0.001$ ) was observed in young patients suffering from coronary artery disease (CAD). hs-CRP was 4.5 times raised than the control.
10.	Zacho J et al. (70)	2008	Copenhagen	Cross-sectional study	N=10276	Genetic polymorphisms within the CRP gene are correlated with a substantial rise in CRP levels, thereby suggesting a potential increase in the risk of ischemic vascular disease.

11.	Mora S et al. (71)	2006	USA	Prospective study	N=27742	The levels of hs-CRP exhibited a positive correlation with the risk of cardiovascular disease.
12.	Luc G. et al. (48)	2003	France	case-control	317-cases Control-607	CRP levels were substantially higher in patients (CHD) group compared to controls with p-value < 0.05.
13.	Ishikawa T et al. (72)	2003	Japan	Cross-sectional	N=27	C-reactive protein (CRP) within atheromatous plaques contributes to the pathogenesis and/or progression of unstable angina pectoris and restenosis following directional coronary atherectomy (DCA)
14.	Haidari M et al. (73)	2001	Canada	Case-control	284-CAD 166-control	C-reactive protein (CRP) is significantly linked to stable coronary artery disease (CAD), and assessing CRP levels could enhance the evaluation of coronary risk in patients with CAD.
15.	Danesh J et al. (74)	2000	London	Nested Case-control	Cases-507 Control-1026	The baseline measurements of C-reactive protein demonstrated a correlation with the future likelihood of coronary heart disease.
16.	Ridker PM et al. (53)	2000	England	Prospective nested case-control	N=28263	hs-CRP concentration were elevated in category having cardiovascular disease than the group free of cardiovascular disease in women.
17.	Heeschen C et al. (75)	2000	USA	Cross-sectional study	N=447	C-reactive protein (CRP) served as an independent predictor for both cardiac risk and the likelihood of undergoing repeated coronary revascularization procedures, including coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty, over the 6-month follow-up period.
18.	Tataru MC et al. (76)	1999	Germany	Case-control	1411-CAD 464-Control	The mean C-reactive protein levels during the early stages of generalized atherosclerosis were greater than those recorded in patients experiencing coronary heart disease
19.	Haverkate F et al. (77)	1997	London, UK	Cross-sectional study	N=2121	Elevated levels of C-reactive protein (CRP) were linked to coronary events in individuals experiencing either stable or unstable angina. Patients exhibiting CRP concentrations in the highest quintile (>3.6 mg/L) faced approximately double the risk of experiencing a coronary event.
20.	Biasucci L M. et al. (58)	1996	USA	Case-control	N=38	CRP concentration were increased (i.e. >3 mg/L) in the subjects with unstable angina than stable angina pectoris.
21.	Liuzzo G et al. (78)	1994	Italy	Cross-sectional study	N=92	C-reactive protein (CRP) serves as an inflammatory marker in the development of CHD, as elevated levels of CRP upon hospital admission are associated with unfavourable outcomes in patients experiencing unstable angina

**Table 10.** Studies showing association of IL-6, TNF-alpha, and CRP with severity of coronary artery disease.

Sl.no	Author's name	S	place	Type of Study	Sample size	Findings
1.	Bouzidi N et al. (26)	2023	Tunisia	Case-control	310- CAD 210- Controls	The levels of IL-6 were found to be correlated with Gensini scores in patients with coronary artery disease (CAD). The levels of IL-6 were found to be correlated with Gensini scores in patients with coronary artery disease (CAD).
2.	Heinisch RH et al. (29)	2022	Brazil	Case-control	20- ACS 20-SA 20- control	Inflammatory markers are linked to the severity of ischaemic disease, exhibiting higher levels in acute coronary syndrome (ACS) compared to stable angina or control subjects.
3.	Zhu M. et al. (66)	2018	China	Case-control	N=579 Cases-492 Cases-87	The Gensini score exhibited a positive correlation with hs-CRP levels, (with a correlation coefficient of $r = 0.361$ and a significance level of $P < 0.01$ .)
4.	Tajfard M et al. (65)	2018	Iran	Case-control	N=2346 Cases-1187 Control-1159	The hs-CRP exhibited a significant correlation with the score associated with coronary artery disease ( $p < 0.01$ ).
5.	Li X. Y. et al. (79)	2018	China	Cross-sectional	N=77 CAD-40 Non-CAD-37	Serum concentration of TNF-like cytokine 1A (TL1A), a component of the TNF superfamily are positively correlated with SYNTAX scores in patients having cardiac surgery.
6.	Min X et al. (80)	2017	China	Cross-sectional	N=149	IL-6 and TNF- alpha significantly increase on increasing severity of ischemic events with $p < 0.005$
7.	Al-Tu'maa FJ et al. (81)	2016	Iraq	Cross-sectional	N=76	A notable and robust positive correlation was observed between the severity of coronary artery disease (CAD) and the serum concentrations of high-sensitivity C-reactive protein (hs-CRP).
8.	Tang J et al. (38)	2015	China	Cross-sectional	N=81	The levels of IL-6 were markedly elevated in the groups with one-vessel, two-vessel, and three-vessel disease when compared to the control group. The levels of IL-6 were markedly reduced in the one-vessel disease group compared to both the two-vessel disease group ( $p\text{-value} < 0.05$ ) and the three-vessel disease group ( $p\text{-value} < 0.01$ ).
9.	Cesari M et al. (47)	2013	USA	Cohort study	N=2225	The levels of TNF-alpha and IL-6 were correlated with the severity of left ventricular dysfunction.
10	Tanindi A et al. (42)	2011	Turkey	Cross-sectional	N=134	IL-6 demonstrated a significant correlation with the Gensini score, which serves as an objective measure of the severity and extent of coronary artery disease (CAD).

11	Gotsman I et al. (44)	2008	Israel	Cross-sectional	N=201	<p>There was a higher prevalence of coronary vessel disease, characterized by over 70% stenosis, among patients as the levels of serum TNF<math>\alpha</math> and IL-6 increased across tertiles.</p> <p>The severity of coronary heart disease, evaluated using the Gensini score, demonstrated independent associations with the inflammatory markers TNF<math>\alpha</math> and IL-6 in patients with both stable and unstable forms of the condition</p>
12	Zebrack JS et al. (82)	2002	USA	Cross-sectional	N=2554	<p>Elevated C-reactive protein (CRP) levels are observed in individuals suffering from mild, moderate, and severe coronary artery disease (CAD) in contrast to patients who present with normal angiograms.</p> <p>CRP - minimal CAD &lt; intermediate CAD &lt; advanced CAD</p>
13	Van Der Meer I M et al. (49)	2002	Netherland	Cohort study	N=7983	<p>IL-6 increases on increasing the size and severity of the lesion.</p>
14	Mahajan N et al. (68)	2009	India	Case-control	N=140 Cases-100 Control-40	<p>Within the CAD group, there is a notable and positive association between the levels of hs-CRP and the severity of coronary artery disease.</p>
15	Biasucci L. M et al. (58)	1996	America	Case-control	N=38	<p>The levels of IL-6 were found to be higher in cases of unstable angina pectoris compared to those with chronic stable angina pectoris.</p> <p>Higher levels of IL-6 are typically present in unstable angina and have a significant association with prognostic implications.</p> <p>There is a positive relationship between the severity of angina and the levels of CRP, with higher levels observed in more severe cases.</p>

significantly, which contributes to systemic inflammation. In contrast, non-obstructive CAD is related to early atherosclerosis consisting of smaller and more stable plaques that are associated with less active inflammation, resulting in lower levels of IL-6. (84)

#### 4.3. Inflammatory Markers in Stable vs. Unstable Angina and ACS

Some of the studies compared serum IL-6, CRP and TNF-alpha levels between stable angina and unstable angina. A study done by Heinisch RH et al. (29) indicated that baseline levels of CRP, IL-6, and TNF were elevated in patients with acute coronary syndrome (ACS) when compared to those with stable angina (SA) or control subjects. In a study done by Doustkami H et al. (30) it was found that cytokine interleukin-6 levels were elevated in the acute myocardial infarction group than stable angina pectoris group and non-CAD category. Also, Ling Y et al. (31) revealed that the ACS group exhibited elevated levels of IL-6 and hs-CRP in contrast to the SAP group. Unlimited death rates common diet Hence, the findings of these studies exhibited the importance of TNF-alpha, IL-6 and CRP in the pathophysiology of unstable angina and acute coronary syndrome. It has been demonstrated that CRP, TNF- $\alpha$  and interleukin-6 have a strong association with the likelihood of cardiac events and is a significant predictive indicator of inflammatory status.

#### 4.4. Inflammatory Markers and Myocardial Infarction

Anderson DR et al. (39) compared serum concentrations of IL-6 between AMI, CAD, & healthy control subjects. They found that serum levels of inteleukin-6 were more raised in group with AMI than in CAD as well as control. Additionally, Doustkami H et al. (30) showed that IL-6 levels were significantly increased in patients with AMI compared with SAP and groups with healthy control. (IL-6 levels-AMI>SAP> healthy control). Maury CPJ et al. (62) found in their study that in individuals having AMI, TNF-alpha levels were significantly greater than those having prolonged chest pain but no myocardial infarction. Patients having MI and prolonged chest pain have higher TNF-alpha levels than healthy control subjects. The rise in myocardial injury and inflammation was associated with heightened TNF- $\alpha$  levels, suggesting that it could worsen heart damage and hinder recovery following an infarction. Blake GJ et al. (85) found that higher levels of CRP were observed in patients with acute myocardial infarction and unstable angina in comparison to those diagnosed with stable angina. Also, Tang J et al. (38) showed ACS group had a significantly

greater hs-CRP than SAP and the control group (p-value<0.01).

#### 4.5. Inflammatory Markers and CAD Severity

Less number of studies showed a link between IL-6, TNF-alpha & CRP with the extent of coronary artery disease. Fifteen studies mentioned in **Table 9** showed that there is a relationship between the levels of TNF-alpha, CRP and IL-6 in serum and the severity of coronary artery disease. Bouzidi N et al. (26) concluded in their study that serum IL-6 levels were substantially raised in group with high Gensini scores against low Gensini scores. Gotsman I et al. (44) also stated patients having more coronary vessel stenosis (> 70% stenosis) also have elevated tertiles of IL-6 and TNF $\alpha$  has a substantial correlation with the number of vessels affected. Furthermore, it was found that patients with stable and unstable CHD showed independent associations between the intensity of coronary disorder (based on the Gensini scoring system) and IL-6. Also, TNF-alpha levels were found to be remarkably linked with CAD in patients with stable angina and acute coronary syndromes. They concluded that IL-6 circulating levels were associated with the Gensini severity score and the count of obstructed coronary vessels, indicating that IL-6 is an important predictor of the severity of CAD.

TNF-alpha was found to be an independent predictor of overall atherosclerotic burden, as evidenced by the count of arteries that were occluded by more than 50% or 70%. Additionally, Zhou et al. (35) noted a considerable association between higher Gensini scores and increased levels of interleukin-6 in postmenopausal women, reinforcing the connection between inflammatory cytokine IL-6 and the extent of CAD. Similarly, Gerin et al. found that interleukin-6 concentrations were noticeably raised in individuals diagnosed with coronary heart disease, showing a correlation with both Gensini and SYNTAX scores, which suggests a connection between plasma interleukin-6 levels and the degree of pathology of the disease. (86) Min X et al. (80) unveiled the association of serum TNF-alpha and the severity of CAD. They stated that TNF- alpha significantly increases increasing severity of ischemic events with p<0.005. Additionally, Li X. Y. et al. (79) revealed that the levels of TNF- alpha-like cytokine 1A (TL1A) is positively correlated with SYNTAX scores in patients having cardiac surgery. To summarize this, the increased inflammatory condition associated with more advanced coronary artery disease is indicated by the increase in IL-6 levels corresponding to higher Gensini scores and syntax scores. This association underscores the significance of inflammation in the mechanisms of atherosclerosis and

indicates its viability as a target for therapeutic intervention in the management of coronary artery disease (CAD). As atherosclerosis progresses, the inflammatory load intensifies, leading to elevated levels of inflammatory cytokine interleukin-6 and tumor necrosis factor-alpha in circulation. As a result, individuals with more significant coronary artery narrowing, indicated by elevated Gensini scores, are likely to show higher IL-6 levels. Increased levels of IL-6 have been consistently linked to both the occurrence and intensity of CAD, with numerous studies showing that high IL-6 and TNF-alpha concentrations correlate with increased arterial stiffness, endothelial dysfunction, and atheromatous plaque formation. Similar to IL-6, elevated serum TNF-alpha is also linked to the pathogenesis of CAD and its severity. This reinforces the concept that IL-6 may serve as a useful biomarker for assessing the inflammatory burden in CAD. A relationship was observed between IL-6 levels and Gensini scores among individuals suffering from coronary heart disease.

Zhu M. et al. (66), Al-Tu'maa FJ et al. (81), Mahajan N et al. (68), Biasucci L. M et al. (58) showed a strong positive association between the severity of CAD and serum levels of hs-CRP. Additionally, Zebrack JS et al. (82) found that elevated C-reactive protein levels are observed in patients diagnosed with mild, moderate, and severe coronary artery disease when contrasted with those who have normal and are free of CAD. (CRP levels- mild CAD<moderate CAD<severe CAD). It is concluded that CRP indicates ongoing inflammation, which contributes to atherosclerosis and the risk of plaque rupture, it serves as a valuable indicator for predicting CAD progression and potential cardiac events. Considering that elevated CRP levels reflect an enhanced inflammatory condition associated with a greater risk, their application in assessing cardiovascular risk and targeting inflammation therapeutically is warranted. Therefore, CRP may serve as a predictor of the progression of CAD or cardiac events as well as a prognostic marker for CAD. (87) Therefore, CRP may serve as a predictor of the progression of CAD or cardiac events. (87) CRP, an acute-phase protein, is produced in reaction to inflammatory cytokines, including IL-6, so, Atherosclerosis is marked by persistent inflammation in the blood vessels, and both systemic and vascular inflammation are indicated by elevated CRP levels. It is concluded that CRP indicates ongoing inflammation, which contributes to atherosclerosis and the risk of plaque rupture, it serves as a valuable indicator for predicting CAD progression and potential cardiac events. Considering that elevated CRP levels reflect an enhanced inflammatory condition associated with a

greater risk, their application in assessing cardiovascular risk and targeting inflammation therapeutically is warranted.

Recent clinical trials, including the CANTOS trial, have yielded strong evidence that directly addressing inflammation particularly the IL-1 $\beta$ /IL-6/CRP pathway can markedly decrease cardiovascular events irrespective of lipid reduction. These results highlight the clinical significance of IL-6 and CRP not only as biomarkers but also as potential therapeutic targets. Incorporating these findings into clinical practice may transform the management of coronary artery disease from a solely risk-factor oriented model to a more inflammatory focussed strategy, thereby facilitating personalized therapies that integrates anti-inflammatory agent with conventional treatment.

## 5. CONCLUSIONS

Elevated levels of inflammatory markers TNF $\alpha$  and IL-6 have been connected to the severity of coronary artery disease in individuals presenting with both stable and unstable coronary conditions. This correlation might reflect a chronic inflammatory load and could act as a marker indicating a heightened risk for serious coronary disease. These provisional observations suggest that the baseline concentration of CRP may serve as a more effective marker for inflammation compared to cytokines in individuals with CAD. IL-6 serves as an effective biomarker indicating the extent of coronary stenosis and significantly contributes to advancement of atherosclerosis. These inflammatory markers can serve as predictors of the progression of CAD as well as prognostic markers. IL-6 has been identified as both a reliable biomarker and a potential therapeutic target. Subsequent research should prioritize interventional studies and mechanistic trials to clarify causality and examine IL-6 modulation as a strategy for lowering cardiovascular risk.

## 6. LIMITATIONS

The systematic review encompassed a limited selection of articles, and it was possible to include only a few prospective and follow-up studies in the analysis.

There are many inflammatory markers involved in the mechanism of pathogenesis of CAD but only few markers were considered for review in this study.

The majority of the research incorporated in our study was carried out at a single institution. Therefore, it is essential to further assess high-quality prospective multi-centre studies.

Differences in study design, populations, interventions, and outcomes might result in heterogeneity, complicating data synthesis and limiting results comparability.

## 7. FUTURE IMPLICATIONS

These biomarkers contributed significantly in risk assessment of CAD which helps in guiding the extent of preventive strategies. This can lead to the addition of supportive tools for better target treatment and to make more precise interventions. As there are a smaller number of studies linking concentration of inflammatory biomarkers IL-6, TNF-alpha, and CRP with the extent of CAD, it can be considered for future research topics.

### Acknowledgment

The authors also wish to thank the Department of biochemistry of Teerthanker Mahaveer Medical college and Research Centre for providing the facilities to conduct this study.

### Conflict of interest

The authors do not have any conflict of interest.

### Funding

The authors received no financial support for the research, authorship, and/or publication of this systematic review.

### Ethical statement

This research did not involve human participants, animal subjects, or any material that requires ethical approval.

## References

- Malakar A. K., Choudhury, D., Halder B., Paul P., Uddin A., & Chakraborty S. A review on coronary artery disease, its risk factors, and therapeutics. *Journal of cellular physiology*,2019; 234(10), 16812-16823.
- Stark B., Johnson, C., & Roth, G. A.. Global prevalence of coronary artery disease: an update from the global burden of disease study. *Journal of the American College of Cardiology*, 2024 83(13\_Supplement), 2320-2320.
- Global B. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. *JAMA oncology*. (2024)
- Rao M., Xavier D., Devi P., Sigamani A., Faruqui A., Gupta R., Kerkar P., Jain R. K., Joshi R., Chidambaram N., Rao D. S., Thanikachalam S., Iyengar S. S., Verghese K., Mohan V., & Pais P. Prevalence, treatments and outcomes of coronary artery disease in Indians: A systematic review. *Indian heart journal*, 2015; 67(4), 302–310. <https://doi.org/10.1016/j.ihj.2015.05.003>
- Gupta R., Mohan I., & Narula J. Trends in Coronary Heart Disease Epidemiology in India. *Annals of global health*,2016;82(2), 307–315. <https://doi.org/10.1016/j.aogh.2016.04.002>
- Krishnan A., Asadullah M., Roy A., Praveen P. A., Singh K., Amarchand R., Gupta R., Ramakrishnan L., Kondal D., Tandon N., Sharma M., Shukla D. K., Prabhakaran D., & Reddy K. S. Change in prevalence of Coronary Heart Disease and its risk between 1991-94 to 2010-12 among rural and urban population of National Capital Region, Delhi. *Indian heart journal*,2020; 72(5), 403–409. <https://doi.org/10.1016/j.ihj.2020.08.008>
- Murthy P. D., Prasad K. T., Gopal P. V., Rao K. V., & Rao R. M. A survey for prevalence of coronary artery disease and its risk factors in an urban population in Andhra Pradesh. *The Journal of the Association of Physicians of India*,2012; 60, 17–20.
- Bhardwaj R., Kandoria A., Marwah R., Vaidya P., Dhiman P., & Singh B. Coronary heart disease in rural population of Himachal—a population based study. *The Journal of the Association of Physicians of India*, 2009; 57, 505–507.
- Kamili M., Dar I., Ali G., Wazir H., & Hussain S. 2007. Prevalence of coronary heart disease in Kashmiris. *Indian heart journal*, 2007; 59(1), 44–49.
- Chow C., Cardona M., Raju P. K., Iyengar S., Sukumar A., Raju R., Colman S., Madhav P., Raju R., Reddy K. S., Celermajer D., & Neal B. Cardiovascular disease and risk factors among 345 adults in rural India--the Andhra Pradesh Rural Health Initiative. *International journal of cardiology*,2007; 116(2), 180–185. <https://doi.org/10.1016/j.ijcard.2006.03.043>
- Libby P., Ridker P. M., & Maseri A. Inflammation and atherosclerosis. *Circulation*, 2002; 105(9), 1135–1143. <https://doi.org/10.1161/hc0902.104353>
- Hajar R. Risk Factors for Coronary Artery Disease: Historical Perspectives. *Heart views : the official journal of the Gulf Heart Association*, 2017; 18(3), 109–114. [https://doi.org/10.4103/HEARTVIEWS.HEARTVIEWS\\_106\\_17](https://doi.org/10.4103/HEARTVIEWS.HEARTVIEWS_106_17)
- Xing Y., & Lin X. Challenges and advances in the management of inflammation in atherosclerosis. *Journal of advanced research*,2024; S2090-1232(24)00253-4. Advance online publication. <https://doi.org/10.1016/j.jare.2024.06.016>
- Fichtlscherer S., Heeschen C., & Zeiher A. M. Inflammatory markers and coronary artery disease. *Current opinion in pharmacology*, 2004; 4(2), 124–131. <https://doi.org/10.1016/j.coph.2004.01.002>
- Madjid M., & Willerson J. T. Inflammatory markers in coronary heart disease. *British medical bulletin*,2011; 100, 23–38. <https://doi.org/10.1093/bmb/ldr043>
- Sproston N. R., & Ashworth J. J. Role of C-Reactive Protein at Sites of Inflammation and Infection. *Frontiers in immunology*,2018; 9, 754. <https://doi.org/10.3389/fimmu.2018.00754>
- Zwaka T. P., Hombach V., & Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. *Circulation*, 2001; 103(9), 1194–1197. <https://doi.org/10.1161/01.cir.103.9.1194>
- Ikonomidis I., Michalakeas C. A., Parissis J., Paraskevaidis I., Ntai K., Papadakis I., Anastasiou-Nana M., & Lekakis J. Inflammatory markers in coronary artery disease. *BioFactors (Oxford, England)*,2012; 38(5), 320–328. <https://doi.org/10.1002/biof.1024>
- Ridker P. M., Buring J. E., Cook N. R., & Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. *Circulation*,2003; 107(3), 391–397. <https://doi.org/10.1161/01.cir.0000055014.62083.05>
- Javed, Q. Clinical implications of tumor necrosis factor-alpha, interleukin-6 and resistin in coronary artery disease. *World Journal of Cardiovascular Diseases*, 2014.
- Tanaka T., Narazaki M., & Kishimoto T. IL-6 in inflammation, immunity, and disease. *Cold Spring Harbor perspectives in biology*,2014 6(10), a016295.

22. Zhang H., & Dhalla N. S. The Role of Pro-Inflammatory Cytokines in the Pathogenesis of Cardiovascular Disease. *International journal of molecular sciences*, 2024; 25(2), 1082. <https://doi.org/10.3390/ijms25021082>.
23. Wells, G, Shea, B, O'Connell, D, et al. (2011) The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. [http://www.ohri.ca/programs/clinical\\_epidemiology/oxford.asp](http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp)
24. Higgins, J. P. T., Savović, J., Page, M. J., El Dib, R., Bad Götze, P., Moher, D., ... & Sterne, J. A. C. (2019). Risk of bias 2: a revised tool for assessing risk of bias in randomized controlled trials. *BMJ*, 366, 1545.
25. Hooijmans, C. M., Moons, K. G., van der Wilt, G. J., van der Beukel, C. M., van Wely, C. A., van der Lee, S. J., & Timmers, L. (2014). SYRCLE's risk of bias tool for animal studies. *BMC Medical Research Methodology*, 14(1), 43
26. Bouzidi N., & Gamra H. Relationship between serum interleukin-6 levels and severity of coronary artery disease undergoing percutaneous coronary intervention. *BMC cardiovascular disorders*, 2023 23(1), 586. <https://doi.org/10.1186/s12872-023-03570-8>
27. Fadhil Jaafar A., Afrisham R., Fadaei R., Farrokhi V., Moradi N., Abbasi A., & Einollahi N. CCN3/NOV serum levels in coronary artery disease (CAD) patients and its correlation with TNF- $\alpha$  and IL-6. *BMC research notes*, 2023 ; 16(1), 306. <https://doi.org/10.1186/s13104-023-06590-x>
28. Djahanpour N., Ahsan N., Li B., Khan H., Connelly K., Leong-Poi H., & Qadura M. A Systematic Review of Interleukins as Diagnostic and Prognostic Biomarkers for Peripheral Artery Disease. *Biomolecules*, 2023 13(11), 1640. <https://doi.org/10.3390/biom13111640>
29. Heinisch R. H., Zanetti C. R., Comin F., Fernandes J. L., Ramires J. A., & Serrano C. V., Jr Serial changes in plasma levels of cytokines in patients with coronary artery disease. *Vascular health and risk management*, 2005; 1(3), 245–250.
30. Doustkami H., Avesta L., Babapour B., Boskabady M. H., Nikoukhesal A., & Aslani M. R. Correlation of Serum Decoy Receptor 3 and Interleukin-6 with Severity of Coronary Artery Diseases in Male Acute Myocardial Infarction Patients. *Acta bio-medica: Atenei Parmensis*, 2021; 92(5), e2021285. <https://doi.org/10.23750/abm.v92i5.9711>
31. Ling Y., Weng H., & Tang S. The relationship between IL-6 levels and the angiographic severity of coronary artery disease following percutaneous coronary intervention in acute coronary syndrome patients. *BMC cardiovascular disorders*, 2021 21(1), 578. <https://doi.org/10.1186/s12872-021-02406-7>
32. Mohammad-Rezaei M., Ahmadi R., Rafiei A., Khaledifar A., Fattahi S., Samiei-Sefat A., Emami S., & Bagheri N. Serum levels of IL-32 in patients with coronary artery disease and its relationship with the serum levels of IL-6 and TNF- $\alpha$ . *Molecular biology reports*, 2021; 48(5), 4263–4271. <https://doi.org/10.1007/s11033-021-06441-7>
33. Gager G. M., Biesinger B., Hofer F., Winter M. P., Hengstenberg C., Jilma B., Eyileten C., Postula M., Lang I. M., & Siller-Matula J. M. Interleukin-6 level is a powerful predictor of long-term cardiovascular mortality in patients with acute coronary syndrome. *Vascular pharmacology*, 2020; 135, 106806. <https://doi.org/10.1016/j.vph.2020.106806>
34. Shen L., Wang S., Ling Y., & Liang W. Association of C1q/TNF-related protein-1 (CTRP1) serum levels with coronary artery disease. *The Journal of international medical research*, 2019; 47(6), 2571–2579. <https://doi.org/10.1177/0300060519847372>
35. Zhou M., Dai W., Cui Y., Liu H., & Li Y. Associations between the IL-6-neutralizing sIL-6R-sgp130 buffer system and coronary artery disease in postmenopausal women. *Annals of translational medicine*, 2020; 8(6), 379. <https://doi.org/10.21037/atm.2020.02.27>
36. Fanola C. L., Morrow D. A., Cannon C. P., Jarolim P., Lukas M. A., Bode C., Hochman J. S., Goodrich E. L., Braunwald E., & O'Donoghue M. L. Interleukin-6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52) Trial. *Journal of the American Heart Association*, 2017; 6(10), e005637. <https://doi.org/10.1161/JAHA.117.005637>
37. Akita K., Isoda K., Sato-Okabayashi Y., Kadoguchi T., Kitamura K., Ohtomo F., Shimada K., & Daida H. An Interleukin-6 Receptor Antibody Suppresses Atherosclerosis in Atherogenic Mice. *Frontiers in cardiovascular medicine*, 2017; 4, 84. <https://doi.org/10.3389/fcvm.2017.00084>
38. Tang J. N., Shen D. L., Liu C. L., Wang X. F., Zhang L., Xuan X. X., Cui L. L., & Zhang J. Y. Plasma levels of C1q/TNF-related protein 1 and interleukin 6 in patients with acute coronary syndrome or stable angina pectoris. *The American journal of the medical sciences*, 2015; 349(2), 130–136. <https://doi.org/10.1097/MAJ.0000000000000378>
39. Anderson D. R., Poterucha J. T., Mikuls T. R., Duryee M. J., Garvin R. P., Klassen L. W., Shurmur S. W., & Thiele G. M. IL-6 and its receptors in coronary artery disease and acute myocardial infarction. *Cytokine*, 2013; 62(3), 395–400. <https://doi.org/10.1016/j.cyto.2013.03.020>
40. Su D., Li Z., Li X., Chen Y., Zhang Y., Ding D., Deng X., Xia M., Qiu J., & Ling W. Association between serum interleukin-6 concentration and mortality in patients with coronary artery disease. *Mediators of inflammation*, 2013, 726178. <https://doi.org/10.1155/2013/726178>
41. IL6R Genetics Consortium Emerging Risk Factors Collaboration, Sarwar N., Butterworth A. S., Freitag D. F., Gregson J., Willeit P., Gorman D. N., Gao P., Saleheen D., Rendon A., Nelson C. P., Braund P. S., Hall A. S., Chasman D. L., Tybjaerg-Hansen A., Chambers J. C., Benjamin E. J., Franks P. W., Clarke R., Wilde A. A., ... Danesh J. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. *Lancet (London, England)*, 2012; 379(9822), 1205–1213. [https://doi.org/10.1016/S0140-6736\(11\)61931-4](https://doi.org/10.1016/S0140-6736(11)61931-4)
42. Tanindi A., Sahinarslan A., Elbeg S., & Cemri M. Relationship Between MMP-1, MMP-9, TIMP-1, IL-6 and Risk Factors, Clinical Presentation, Extent and Severity of Atherosclerotic Coronary Artery Disease. *The open cardiovascular medicine journal*, 2011; 5, 110–116. <https://doi.org/10.2174/1874192401105010110>
43. Saremi A., Anderson R. J., Luo P., Moritz T. E., Schwenke D. C., Allison M., Reaven P. D., & VADT Association between IL-6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT). *Atherosclerosis*, 2009; 203(2), 610–614. <https://doi.org/10.1016/j.atherosclerosis.2008.07.031>
44. Gotsman I., Stabholz A., Planer D., Pugatsch T., Lapidus L., Novikov Y., Masrawa S., Soskolne A., & Lotan C. Serum cytokine tumor necrosis factor-alpha and interleukin-6 associated with the severity of coronary artery disease: indicators of an active inflammatory burden?. *The Israel Medical Association journal : IMAJ*, 2008; 10(7), 494–498.
45. Schlitt A., Heine G. H., Blankenberg S., Espinola-Klein C., Doppeide J. F., Bickel C., Lackner K. J., Iz M., Meyer J., Darius H., & Rupprecht H. J. CD14+CD16+ monocytes in coronary artery disease and their relationship to serum TNF-alpha levels. *Thrombosis and haemostasis*, 2004; 92(2), 419–424. <https://doi.org/10.1160/TH04-02-0095>
46. Brueckmann M., Bertsch T., Lang S., Sueselbeck T., Wolpert C., Kaden J. J., Jaramillo C., Huhle G., Borggreffe M., & Haase K. K. Time course of systemic markers of inflammation in patients presenting with acute coronary syndromes. *Clinical chemistry and laboratory medicine*, 2004; 42(10), 1132–1139. <https://doi.org/10.1151/CCLM.2004.232>
47. Cesari M., Penninx B. W., Newman A. B., Kritchevsky S. B., Nicklas B. J., Sutton-Tyrrell K., Rubin S. M., Ding J., Simonsick E. M., Harris T. B., & Pahor M. Inflammatory markers and onset of cardiovascular events:

- results from the Health ABC study. *Circulation*, 2003; 108(19), 2317–2322. <https://doi.org/10.1161/01.CIR.0000097109.90783.FC>
48. Luc G., Bard J. M., Juhan-Vague I., Ferrieres J., Evans A., Amouyel P., Arveiler D., Fruchart J. C., Ducimetiere P., & PRIME Study Group C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study. *Arteriosclerosis, thrombosis, and vascular biology*, 2003; 23(7), 1255–1261. <https://doi.org/10.1161/01.ATV.0000079512.66448.1D>
49. van der Meer I. M., de Maat M. P., Bots M. L., Breteler M. M., Meijer J., Kiliaan A. J., Hofman A., & Wittteman J. C. Inflammatory mediators and cell adhesion molecules as indicators of severity of atherosclerosis: the Rotterdam Study. *Arteriosclerosis, thrombosis, and vascular biology*, 2002; 22(5), 838–842. <https://doi.org/10.1161/01.atv.0000016249.96529.b8>
50. Jenny N. S., Tracy R. P., Ogg M. S., Luong le A., Kuller L. H., Arnold A. M., Sharrett A. R., & Humphries S. E. In the elderly, interleukin-6 plasma levels and the -174G>C polymorphism are associated with the development of cardiovascular disease. *Arteriosclerosis, thrombosis, and vascular biology*, 2002; 22(12), 2066–2071. <https://doi.org/10.1161/01.atv.0000040224.49362.60>
51. Koukkunen H., Penttilä K., Kempainen A., Halinen M., Penttilä I., Rantanen T., & Pyörälä K. C-reactive protein, fibrinogen, interleukin-6 and tumour necrosis factor-alpha in the prognostic classification of unstable angina pectoris. *Annals of medicine*, 2001; 33(1), 37–47. <https://doi.org/10.3109/07853890109002058>
52. Lindmark E., Diderholm E., Wallentin L., & Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. *JAMA*, 2001; 286(17), 2107–2113. <https://doi.org/10.1001/jama.286.17.2107>
53. Ridker P. M., Hennekens C. H., Buring J. E., & Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. *The New England journal of medicine*, 2000; 342(12), 836–843. <https://doi.org/10.1056/NEJM200003233421202>
54. Ridker P. M., Rifai N., Stampfer M. J., & Hennekens C. H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. *Circulation*, 2000; 101(15), 1767–1772. <https://doi.org/10.1161/01.cir.101.15.1767>
55. Schieffer B., Schieffer E., Hilfiker-Kleiner D., Hilfiker A., Kovanen P. T., Kaartinen M., Nussberger J., Harringer W., & Drexler H. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. *Circulation*, 2000 101(12), 1372–1378. <https://doi.org/10.1161/01.cir.101.12.1372>
56. Huber S. A., Sakkinen P., Conze D., Hardin N., & Tracy R. Interleukin-6 exacerbates early atherosclerosis in mice. *Arteriosclerosis, thrombosis, and vascular biology*, 1999; 19(10), 2364–2367. <https://doi.org/10.1161/01.atv.19.10.2364>
57. Biasucci L. M., Liuzzo G., Fantuzzi G., Caligiuri G., Rebuzzi A. G., Ginnetti F., Dinarello C. A., & Maseri A. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. *Circulation*, 1999; 99(16), 2079–2084. <https://doi.org/10.1161/01.cir.99.16.2079>
58. Biasucci LM, Vitelli A, Liuzzo G, Altamura S, Caligiuri G, Monaco C, Rebuzzi AG, Ciliberto G, Maseri A. Elevated levels of interleukin-6 in unstable angina. *Circulation*. 1996;94(5):874–7. doi:10.1161/01.cir.94.5.874.
59. Rus H. G., Vlaicu R., & Niculescu F. Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall. *Atherosclerosis*, 1996; 127(2), 263–271
60. Lei L., Xiong Y., Chen J., Yang J. B., Wang Y., Yang X. Y., Chang C. C., Song B. L., Chang T. Y., & Li B. L. TNF-alpha stimulates the ACAT1 expression in differentiating monocytes to promote the CE-laden cell formation. *Journal of lipid research*, 2009; 50(6), 1057–1067. <https://doi.org/10.1194/jlr.M800484-JLR200>
61. Ridker P. M., Rifai N., Pfeffer M., Sacks F., Lepage S., & Braunwald E. Elevation of tumor necrosis factor- $\alpha$  and increased risk of recurrent coronary events after myocardial infarction. *Circulation*, 2000; 101(18), 2149–2153.
62. Maury C. P. J., & Teppo A. M. Circulating tumour necrosis factor- $\alpha$  (cachectin) in myocardial infarction. *Journal of internal medicine*, 1989; 225(5), 333–336.
63. Khandelwal V., Kapoor A., Kazmi D., Sinha A., Kashyap S., Khanna R., ... & Goel P. Exploring the association of fibrinogen and CRP with the clinical spectrum of CAD and periprocedural outcomes in patients undergoing percutaneous coronary interventions. *Annals of Cardiac Anaesthesia*, 2022; 25(1), 34–40.
64. Zhou J, Li L, Ji X, Zhang X, Dai C, Wang S. Correlation of Serum IL 1 $\beta$ , IL 6, and hsCRP levels with Infarct Core and Ischemic Penumbra Volume in Acute Ischemic Stroke. [Preprint]. ResearchGate; 2022. <https://doi.org/10.21203/rs.3.rs-1882454/v2>
65. Tajfard M., Tavakoly Sany S. B., Avan A., Latiff L. A., Rahimi H. R., Moohebbati M., ... & Bin Abd Mutalib M. S. Relationship between serum high sensitivity C-reactive protein with angiographic severity of coronary artery disease and traditional cardiovascular risk factors. *Journal of cellular physiology*, 2019; 234(7), 10289–10299. <https://doi.org/10.1002/jcp.27945>
66. Zhu M., Lin J., Wang C., Yang M., Lv H., Yang M., ... & Jiang J. The relationship among angiotensinogen genes polymorphisms and hs-CRP and coronary artery disease. *Journal of Clinical Laboratory Analysis*, 2019; 33(5), e22881.
67. Pan H. C., Sheu W. H. H., Lee W. J., Lee W. L., Liao Y. C., Wang K. Y., ... & Liang, K. W. Coronary severity score and C-reactive protein predict major adverse cardiovascular events in patients with stable coronary artery disease (from the Taichung CAD study). *Clinica Chimica Acta*, 2015; 445, 93–100.
68. Mahajan N., Malik N., Bahl A., Sharma Y., & Dhawan V. Correlation among soluble markers and severity of disease in non-diabetic subjects with pre-mature coronary artery disease. *Molecular and Cellular Biochemistry*, 2009; 330, 201–209.
69. Sharma S. B., Garg S., Veerwal A., & Dwivedi S. hs-CRP and oxidative stress in young CAD patients: a pilot study. *Indian journal of clinical biochemistry*, 2008; 23, 334–336.
70. Zacho J., Tybjaerg-Hansen A., Jensen J. S., Grande P., Sillesen H., & Nordestgaard B. G. Genetically elevated C-reactive protein and ischemic vascular disease. *New England Journal of Medicine*, 2008 359(18), 1897–1908.
71. Mora S., Rifai N., Buring J. E., & Ridker P. M. Additive value of immunoassay-measured fibrinogen and high-sensitivity C-reactive protein levels for predicting incident cardiovascular events. *Circulation*, 2006; 114(5), 381–387.
72. Ishikawa T., Hatakeyama K., Imamura T., Date H., Shibata Y., Hikichi Y., Asada Y., & Eto T. Involvement of C-reactive protein obtained by directional coronary atherectomy in plaque instability and developing restenosis in patients with stable or unstable angina pectoris. *The American journal of cardiology*, 2003; 91(3), 287–292. [https://doi.org/10.1016/s0002-9149\(02\)03156-9](https://doi.org/10.1016/s0002-9149(02)03156-9)
73. Haidari M., Javadi E., Sadeghi B., Hajilooi M., & Ghanbili J. Evaluation of C-reactive protein, a sensitive marker of inflammation, as a risk factor

- for stable coronary artery disease. *Clinical biochemistry*, 2011; 34(4), 309-315.
74. Danesh J., Whincup P., Walker M., Lennon L., Thomson A., Appleby P, Gallimore, J. R., & Pepys, M. B. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. *BMJ (Clinical research ed.)*, 2000; 321(7255), 199-204. <https://doi.org/10.1136/bmj.321.7255.199>
75. Heeschen C., Hamm C. W., Bruemmer J., Simoons M. L., & CAPTURE investigators. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. *Journal of the American College of Cardiology*, 2000; 35(6), 1535-1542.
76. Tataru M. C., Heinrich J., Junker R., Schulte H., Von Eckardstein A., Assmann G., & Koehler E. C-reactive protein and the severity of atherosclerosis in myocardial infarction patients with stable angina pectoris. *European Heart Journal*, 2000; 21(12), 1000-1008.
77. Haverkate E., Thompson S. G., Pyke S. D., & Gallimore J. R. Production of C-reactive protein and risk of coronary events in stable and unstable angina. *The Lancet*, 1997; 349(9050), 462-466.
78. Liuzzo G., Biasucci L. M., Gallimore J. R., Grillo R. L., Rebuffi A. G., Pepy, M. B., & Maseri A. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. *New England journal of medicine*, 1994; 331(7), 417-424.
79. Li X. Y., Hou H. T., Chen H. X., Wang Z. Q., & He G. W. Increased circulating levels of tumor necrosis factor-like cytokine 1A and decoy receptor 3 correlate with SYNTAX score in patients undergoing coronary surgery. *Journal of International Medical Research*, 2018; 46(12), 5167-5175.
80. Min X., Lu M., Tu S., Wang X., Zhou C., Wang S., Pang S., Qian J., Ge Y., Guo Y., Xu D., & Cao K. Serum Cytokine Profile in Relation to the Severity of Coronary Artery Disease. *BioMed research international*, 2017, 4013685. <https://doi.org/10.1155/2017/4013685>
81. Al-Tu'maa F. J., Abd-Yasera Z., & Al-Naffi K. O. Association between hs-CRP levels and the severity of coronary atherosclerosis. *J Contemp Med Sci*, 2017; 2(6), 42-44.
82. Zebrack J. S., Muhlestein J. B., Horne B. D., Anderson J. L., & Intermountain Heart Collaboration Study Group C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina. *Journal of the American College of Cardiology*, 2002; 39(4), 632-637. [https://doi.org/10.1016/s0735-1097\(01\)01804-6](https://doi.org/10.1016/s0735-1097(01)01804-6)
83. Ferencik M., Mayrhofer T., Lu M. T., Bittner D. O., Emami H., Puchner S. B., Meyersohn N. M., Ivanov A. V., Adami E. C., Voora D., Ginsburg G. S., Januzzi J. L., Douglas P. S., & Hoffmann U. Coronary Atherosclerosis, Cardiac Troponin, and Interleukin-6 in Patients With Chest Pain: The PROMISE Trial Results. *JACC. Cardiovascular imaging*, 2022; 15(8), 1427-1438. <https://doi.org/10.1016/j.jcmg.2022.03.016>
84. Kamtchum-Tatuene J., Saba L., Heldner M. R., Poorthuis M. H. F., de Borst G. J., Rundek T., Kakkos S. K., Chaturvedi S., Topakian R., Polak J. F., Jickling G. C., & Carotid Atherosclerosis and Stroke Collaboration (CASCO). Interleukin-6 Predicts Carotid Plaque Severity, Vulnerability, and Progression. *Circulation research*, 2022; 131(2), e22-e33. <https://doi.org/10.1161/CIRCRESAHA.122.320877>
85. Blake G. J., & Ridker P. M. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. *Journal of the American College of Cardiology*, 2003, 41(4S), S37-S42.
86. Gerin F., Durmuş E., Yaman A., Sünbül M., Mammadov C., Bozbay M., Sari I & Kıvrak, T. Relation of interleukin-6 level with coronary artery disease severity in patients undergoing coronary angiography. *European Journal of Therapeutics*, 2017 23(3), 117-12
87. Gotto Jr, A. M. Role of C-reactive protein in coronary risk reduction: focus on primary prevention. *The American journal of cardiology*, 2007 99(5), 718-725.